Bevacizumab in the treatment of colorectal cancer

被引：23

作者：

Cilley, Jeffrey C. ^{[1
]}

Barfi, Keren ^{[1
]}

Benson, Al B., III ^{[1
]}

Mulcahy, Mary F. ^{[1
]}

机构：

[1] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2007年 / 7卷 / 05期

关键词：

bevacizumab; colorectal cancer; VEGF;

D O I：

10.1517/14712598.7.5.739

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Colorectal cancer is a common disease with therapy that has a proven effectiveness in the adjuvant and metastatic setting. Bevacizumab, a vascular endothelial growth factor inhibitor, is an antiangiogenesis monoclonal antibody that has benefit in response rate and overall survival when used in combination with existing metastatic colorectal cancer regimens. It is well tolerated with a few important side effects to be cognizant of, including hypertension, arterial thrombosis and bowel perforation. Existing treatment and research strategies are examining its use in the adjuvant setting or in combination with other angiogenesis inhibitors.

引用

页码：739 / 749

页数：11

共 55 条

[1]

Bates David, 2003, Curr Opin Investig Drugs, V4, P1468

[2] Update on clinical trials targeting vascular endothelial growth factor in cancer [J].

Bergsland, EK .

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2004, 61 (21) :S12-S20

[3]

Borgström P, 1999, ANTICANCER RES, V19, P4203

[4]

Bruns CJ, 2000, CANCER, V89, P488, DOI 10.1002/1097-0142(20000801)89:3<488::AID-CNCR3>3.3.CO

[5]

2-O

[6] Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele [J].

Carmeliet, P ;

Ferreira, V ;

Breier, G ;

Pollefeyt, S ;

Kieckens, L ;

Gertsenstein, M ;

Fahrig, M ;

Vandenhoeck, A ;

Harpal, K ;

Eberhardt, C ;

Declercq, C ;

Pawling, J ;

Moons, L ;

Collen, D ;

Risau, W ;

Nagy, A .

NATURE, 1996, 380 (6573) :435-439

[7]

CASSIDY J, 2007, AM SOC CLIN ONC GAST

[8] Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: An NCI Treatment Referral Center trial TRC-0301 [J].

Chen, Helen X. ;

Mooney, Margaret ;

Boron, Matthew ;

Vena, Don ;

Mosby, Kimberly ;

Grochow, Louise ;

Jaffe, Carl ;

Rubinstein, Lawrence ;

Zwiebel, James ;

Kaplan, Richard S. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (21) :3354-3360

[9] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].

Cunningham, D ;

Humblet, Y ;

Siena, S ;

Khayat, D ;

Bleiberg, H ;

Santoro, A ;

Bets, D ;

Mueser, M ;

Harstrick, A ;

Verslype, C ;

Chau, I ;

Van Cutsem, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345

[10] Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial [J].

Demetri, George D. ;

van Oosterom, Allan T. ;

Garrett, Christopher R. ;

Blackstein, Martin E. ;

Shah, Manisha H. ;

Verweij, Jaap ;

McArthur, Grant ;

Judson, Ian R. ;

Heinrich, Michael C. ;

Morgan, Jeffrey A. ;

Desai, Jayesh ;

D Fletcher, Christopher ;

George, Suzanne ;

Bello, Carlo L. ;

Huang, Xin ;

Baum, Charles M. ;

Casali, Paolo G. .

LANCET, 2006, 368 (9544) :1329-1338

← 1 2 3 4 5 6 →